Back to results
US 2023/0212263 A1Published application
Methods and compositions for modified factor ix fusion proteins
AssigneeThe University of North Carolina at Chapel Hill
InventorTal Kafri
Life of this patent
Estimating the term…
Abstract
The present invention provides Factor IX fusion proteins with higher specific activity and a longer useful clotting function relative to wild type or non-modified Factor IX protein.
Claims5
A PKR-deficient packaging cell that generates an integration-competent lentiviral vector that comprises an expression cassette in opposite orientation to long terminal repeats (LTRs) of the vector genome and a self-inactivating 3′ U3.
Dependencies are inferred from the claim text.